TickerFacts.

Black Hawk Acquisition Corp (BKHA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$650.3K
Year ended 2025-11-30
-$560.1K
Trailing 12 months to 2026-08-31
2024-11-30: -$553.7K2025-11-30: -$650.3K-$650.3K
2024-11-30 Operating Cash Flow (USD) 2025-11-30
Period endedOperating Cash FlowChange YoYSource filing
2025-11-30-$650.3Kn/m2026-03-06, From 2024-12-01
2024-11-30-$553.7Kn/a2026-03-06, From 2023-12-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Black Hawk Acquisition Corp (BKHA)2025-11-30-$650.3Kn/m
Pluri Inc. (PLUR)2026-06-30-$19.59Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30-$4.47Mn/m
CEL SCI Corp (CVM)2025-09-30-$17.12Mn/m
Atara Biotherapeutics, Inc. (ATRA)2025-12-31-$50.94Mn/m
Curis Inc (CRIS)2025-12-31-$27.20Mn/m
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$51.83Mn/m
IN8BIO, Inc. (INAB)2025-12-31-$12.71Mn/m
Inmune Bio, Inc. (INMB)2025-12-31-$22.58Mn/m

Compare BKHA, PLUR, CSBR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗